Section Arrow
BMEA.NASDAQ
- Biomea Fusion
Quotes are at least 15-min delayed:2024/05/16 04:56 EDT
Last
 13.24
+0.87 (+7.03%)
Day High 
13.33 
Prev. Close
12.37 
1-M High
13.37 
Volume 
929.65K 
Bid
5.3
Ask
16.8
Day Low
12.515 
Open
12.59 
1-M Low
10.22 
Market Cap 
444.63M 
Currency USD 
P/E -- 
%Yield
10-SMA 11.71 
20-SMA 11.3 
50-SMA 13.4 
52-W High 43.69 
52-W Low 8.125 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.55/-4.07
Enterprise Value
452.46M
Balance Sheet
Book Value Per Share
3.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 04:56 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.